Rosemont Announces New CEO – Alok Sonig

On behalf of the Board of Directors, we are pleased to announce that Alok Sonig has been appointed Chief Executive Officer, effective January 1, 2026.

With almost three decades in pharmaceuticals, Alok joins us from Baxter International Inc where he was most recently serving as Executive VP and Group President, Pharmaceuticals for their global business. Prior to this role, he served as the CEO at Lupin Pharmaceuticals (US Pharmaceuticals, Global Head of R&D and Biosimilars) and Dr Reddy’s Laboratories as CEO of Developed Markets (US, Canada, Europe and Japan). Previously, he also spent nearly 15 years at Bristol-Myers Squibb, where he held several executive positions in general management, global strategy, and marketing.

He is recognized for driving growth, enhancing performance, and leading high-impact teams. At Baxter, he oversaw significant transformation, including revenue growth, accelerated R&D, regulatory and quality compliance improvements, with operational excellence.

He has also served as chairman of the Association for Accessible Medicines and is an advisory board member at the Kogod School of Business, American University. He holds an engineering degree from Punjab Engineering College and an MBA from American University.

The Board is confident that his strategic vision and leadership will guide our company’s next phase of growth.

 

ROS000238-003 Dec 2025